[Induction of tolerance of heterologous protein in therapy with antilymphocytic globulin in man].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D016039:Corneal Transplantation; D003882:Dermatomyositis / Q000628:therapy; D005260:Female; D006736:Horses / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance; D007116:Immunization, Passive; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation; D007945:Leukemia, Lymphoid / Q000628:therapy; D008297:Male; D009103:Multiple Sclerosis / Q000628:therapy; D012859:Sjogren's Syndrome / Q000628:therapy; D013256:Steroids / Q000627:therapeutic use; D013997:Time Factors; D014181:Transplantation Immunology; D014184:Transplantation, Homologous; D005719:gamma-Globulins / Q000627:therapeutic use
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D013256:Steroids; D005719:gamma-Globulins; D001379:Azathioprine
Studien zur Toleranzerzeugung gegenüber heterologem Protein bei der therapie mit antilymphozytärem Globulin beim Menschen.